Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY ...
Sarepta Therapeutics says its RNA therapy for Duchenne muscular dystrophy (DMD) could be more effective than its existing drugs, but a dose-escalation study also dug up some new—and serious—adverse ...
Capricor Therapeutics, Inc. (CAPR) has a significant catalyst that is rapidly approaching, which could change the scope of this biotech. This would be regarding the release of top-line data from ...
Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks Consensus Estimate of a loss of 15 cents. Earnings rose 99% year over year, ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet ...
- Potential first-in-class gene editing approach designed for dystrophin gene correction leading the body to produce a functional dystrophin protein applicable for majority of DMD patients (up to ~60% ...
Offered jointly between our School of Dental Medicine and School of Medicine, the DMD/MPH program is centered on four key themes: Health and wellbeing, Disease processes, Restoration of health, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback